ImmunityBio

News

ImmunityBio bags elusive label extension for Anktiva

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

News

ImmunityBio warned by FDA over 'misleading' Anktiva content

The FDA has sent a warning letter to ImmunityBio over "false and misleading" comments made by executive chair, billionaire Patrick Soon-Shiong.

News

ImmunityBio rises as route opens to broader Anktiva label

Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Oncology

ASCO 2025 interview with Dr Sandeep Reddy

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

News

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.

ImmunityBio bags elusive label extension for Anktiva

ImmunityBio warned by FDA over 'misleading' Anktiva content

ImmunityBio rises as route opens to broader Anktiva label

ESMO25: Harnessing the innate and the adaptive immune respon...

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

Bayer hits "turning point" in recovery plan, says CEO

Discover a new era of healthcare panel engagement: Grounded ...

ImmunityBio

Editor's Picks